Posted innews Ophthalmology
High-Dose Aflibercept 8 mg Demonstrates Sustained Visual Gains and Durability in Polypoidal Choroidal Vasculopathy
This post hoc analysis of the PULSAR trial reveals that aflibercept 8 mg provides noninferior visual outcomes and comparable anatomic regression to standard 2 mg dosing in PCV patients, while allowing for significantly extended treatment intervals and reduced injection burden.
